SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing intense investor scrutiny driven by legal challenges regarding NCAA trademarks and ongoing debates over the impact of emerging prediction market platforms. The community is sharply divided, with many actively loading up on short positions while others debate whether recent volatility represents a long-term accumulation opportunity.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is trending as investors aggressively rotate into the fund to gain exposure to high-profile private companies, specifically SpaceX and Anthropic, ahead of expected IPO activity. The community is actively debating the fund's premium over its Net Asset Value compared to alternative vehicles, while closely watching for a potential short squeeze driven by the stock's relatively low float.

The Shrimp Army

SHRIMPS is gaining traction as part of a broader trend of fish-themed meme coins, with community members debating its potential as a high-volatility runner compared to similar assets. While some investors are optimistic about its rapid momentum, others express caution regarding the risks of quick market reversals typical of the sector.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over high capital expenditures and intense competition within the AI landscape. The community remains deeply divided, with many traders expressing frustration over the stock's persistent underperformance while others view the current valuation as a long-term buying opportunity.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing a significant surge in momentum as investors react to promising early clinical trial data from its new siRNA pipeline targeting rare muscle disorders, FSHD1 and DM1. While the community is actively debating the potential for a short squeeze and long-term valuation recovery, there is focused excitement regarding the company's best-in-class delivery platform and the strategic pivot toward these new programs.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is experiencing significant downward pressure as investors react to the launch of a private-label energy drink by Costco, sparking concerns over market share erosion and margin compression. Despite the company's strong brand loyalty and recent growth, community discussion is sharply divided between those viewing the decline as a manipulative overreaction to noise and those concerned about long-term valuation and potential leadership failures.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors scrutinize the brokerage's technical infrastructure following a widespread system outage that prevented users from logging in, accessing funds, or executing trades. Community sentiment is deeply polarized, with many users expressing frustration over platform reliability and restrictive trading policies, while others debate the potential impacts of a suspected cyberattack versus routine technical failures.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is currently facing significant volatility and market scrutiny following a critical short report from Culper Research, which has sparked intense debate between investors defending the company's fundamentals and those concerned by the allegations of channel stuffing. While management has dismissed the report as inaccurate and speculative, shareholders are actively monitoring institutional responses and awaiting a formal rebuttal to provide the clarity needed to stabilize investor sentiment.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Orcasm is trending as part of a surge in marine-themed meme coins, with community members actively discussing its potential for rapid price movement and speculative growth. Investors are debating the project's viability, with many comparing it to other ocean-themed tokens and highlighting it as a high-risk, high-reward opportunity.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is experiencing significant volatility following a mixed earnings report where record bookings and a new one billion dollar buyback plan were overshadowed by a revenue miss and cautious guidance. The community is sharply divided, with some investors viewing the stock as deeply undervalued and a prime buyback candidate, while others are frustrated by consistent underperformance and intensifying competitive pressure from Uber.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.

Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated a "buy" rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday...

<ul class="summary-bullets"><li>The start of the trial triggered a second $10 million milestone payment to Lexicon.</li><li>The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants.</li><li>The trial is expected to be completed in early 2027, Novo said.</li></ul>Novo Nordisk (NVO) is pushing deeper into next-gen obesity treatments. The drugmaker announced on Monday that it has initiated a Phase 1 study of LX9851, Lexicon Pharmaceuticals’ oral non-incretin drug candidate for obesity and related metabolic disorders.&nbsp;This adds to Novo’s obesity treatment pipeline, which also features the semaglutide injection, famously known as Wegovy.&nbsp;At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> climbed 1%, while&nbsp;<a href="https://stocktwits.com/symbol/LXRX">Lexicon Pharmaceuticals’ (LXRX) stock</a> traded over 5% higher.<h2 class="st-heading-2">Novo’s $10 Million Milestone Payment To Lexicon</h2>The start of the trial triggered a second $10 million milestone payment to Lexicon under their licensing deal signed in March 2025. The agreement gives Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible to receive up to $1 billion in total milestone payments, as well as royalties on future sales.The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants. The trial is expected to be completed in early 2027.“LX9851 offers a novel approach to the treatment of obesity and related metabolic conditions. It is an important addition to our pipeline of potential treatment options as we look to meet the diverse needs of people living with obesity, diabetes and their associated comorbidities,” said Jacob Sten Petersen, Senior Vice President and Head of Global Research at Novo Nordisk.&nbsp;<h2 class="st-heading-2">Lilly’s&nbsp;Experimental Diabetes Pill Outperforms Oral Semaglutide&nbsp;</h2>This comes days after&nbsp;Eli Lilly and Company (LLY) announced that its experimental diabetes pill, Orforglipron, outperformed oral semaglutide in a large Phase 3 study, delivering stronger reductions in blood sugar and greater weight loss over 52 weeks. Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.Drug developers are racing to tap the booming obesity market, currently led by injectables like Wegovy and Eli Lilly’s Zepbound.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for NVO and LXRX remained in the ‘bearish’ zone over the past 24 hours.One user called LXRX’s price point “attractive.”<stembedurl>https://stocktwits.com/macrossluvsrobotech/message/648275638</stembedurl>Another user was skeptical about Novo’s forecast.<stembedurl>https://stocktwits.com/Golferhack12/message/648300759</stembedurl>Year-to-date, NVO stock fell 29% while LXRX shares have gained more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Advances Obesity Pipeline With Early-Stage Oral Drug Trial From Lexicon Deal

The trial is part of a licensing deal between Novo and Lexicon that allows Novo to develop and commercialize the drug.

Equity

XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study

Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.

Citigroup Forecasts Strong Price Appreciation for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Citigroup lifted their price objective on Lexicon Pharmaceuticals from $2.10 to $2.30 and gave the company a "buy" rating in a report on Tuesday...

What is HC Wainwright's Estimate for LXRX Q1 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for Lexicon Pharmaceuticals in a report issued on Thursday, March 5th. HC...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 5.8% Following Earnings Beat

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 5.8% Following Earnings Beat...

FY2027 Earnings Forecast for LXRX Issued By HC Wainwright

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at HC Wainwright issued their FY2027 EPS estimates for Lexicon Pharmaceuticals in a research report issued on Thursday...

Lexicon Pharmaceuticals Q4 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) outlined progress across three late-stage programs and reported sharply lower operating expenses during its fourth-quarter and full-year 2025 earnings call held...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down - Should You Sell?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down - Should You Sell...

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

LXRX
Lexicon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LXRX News

LXRXLexicon Pharmaceuticals Inc